OPK Opko Health Inc.

1.96
+0.06  (+3%)
Previous Close 1.9
Open 1.92
Price To Book 0.7
Market Cap 1,206,578,048
Shares 615,601,045
Volume 2,779,602
Short Ratio
Av. Daily Volume 4,023,921

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data March 21, 2019 met primary endpoint. Phase 3 trial planned.
OPK88003
Obesity and diabetes
Phase 2a trial planned for 2H 2018.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2a trial planned for 2H 2018.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial suspension announced January 31, 2019.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 initial open label data due 4Q 2019.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 data due 4Q 2019.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. Analysts Suggest 3 Falling Knives
  2. OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
  3. Opko Health (OPK) Q2 2019 Earnings Call Transcript
  4. Edited Transcript of OPK earnings conference call or presentation 7-Aug-19 8:30pm GMT
  5. OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates
  6. OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results
  7. A Preview Of Opko Health's Q2 Earnings
  8. OPKO Health to Report Second Quarter 2019 Financial Results on August 7, 2019
  9. BIOREFERENCE LABORATORIES SELECTED AS PREFERRED LABORATORY PROVIDER BY THE IPA ASSOCIATION OF AMERICA
  10. Earnings Preview: OPKO Health (OPK) Q2 Earnings Expected to Decline
  11. Is OPKO Health, Inc.'s (NASDAQ:OPK) CEO Pay Fair?
  12. Weekly CEO Buys Highlight
  13. Weekly Top Insider Buys Highlight for the Week of July 12
  14. Do Options Traders Know Something About OPKO Health (OPK) Stock We Don't?
  15. OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers
  16. BioReference Laboratories Forms a Strategic Collaboration with SOMOS to Improve Health Outcomes of Underserved New Yorkers
  17. Here’s What Hedge Funds Think About Opko Health Inc. (OPK)
  18. Why OPKO Health Stock Jumped Today
  19. Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test
  20. OPKO Health Submits De Novo Request to the U.S. FDA for the 4Kscore® Test